Global Toxoid Vaccine Market - 2023-2030

Global Toxoid Vaccine Market - 2023-2030

Global Toxoid Vaccine Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.

Toxoid vaccines use toxoids (as antigens) to induce an immune response in protecting against diseases caused by toxins secreted by specific bacteria. Compared to other vaccines, toxoid vaccines are more stable and less susceptible to damage caused by temperature, humidity, or light. A course of toxoid vaccines induces long-lasting immunity against bacterial diseases such as tetanus and diphtheria.

Approximately 20 to 60% of adults become susceptible to diphtheria because of waning vaccine-induced immunity and failure to receive recommended booster immunization. In the United States, every ten years all adults should get tetanus vaccine with complete prior immunization against tetanus and diphtheria. At least one of those doses should be with Tdap in adults aged 19 years and older who had not received Tdap previously.

Market Dynamics

Increasing government initiatives

Increasing Government initiatives and campaigns conducted by companies during the year are expanding the knowledge of vaccinations and immunizations among infants and adults. For instance, in July 2022, the Government of Indonesia is leading catch-up efforts to address a backslide in childhood immunization caused by COVID-19, such as SIAs and PIRI by the World Health Organisation.

In June 2023, Ukraine received 120,000 doses of diphtheria–tetanus–pertussis (DTP) vaccine from UNICEF to ensure the uninterrupted availability of vaccines for routine immunization programs. These free doses given to the public increase awareness about health and diseases related to tetanus, diphtheria, and tetanus.

Additionally, in January 2023, Panacea Biotec, on humanitarian grounds, donated 125,000 single-dose vials (SDVs) of its WHO Prequalified Pentavalent vaccine, Easyfive-TT, to the Ministry of Health of the Republic of Cuba, for use in Cuba National Health System, specifically in the expanded immunization program due to current ongoing shortage of the wP based Pentavalent Vaccine in Cuba.

Furthermore, Increasing awareness about vaccinations among people, rising advancements in vaccine discoveries, increased pace of vaccine developments, and immunization campaigns are a few factors that drive the market in the forthcoming period.

Side effects of toxoid vaccine

Everyone is not eligible to get toxoid vaccines due to possible side effects. Nausea, loss of appetite, and allergies can be a few plausible side effects. For instance, according to Centers for Disease Control and Prevention, a person who has ever had a life-threatening allergic reaction after a previous dose of diphtheria, tetanus, or pertussis-containing vaccine or has a severe allergy to any part of this vaccine should not get Tdap vaccine. Tdap should be deferred until neurologic status is clarified and stabilized.

Segment Analysis

The global toxoid vaccine is segmented based on disease type, vaccine type, age group, end-user, and region.

The neonates segment accounted for approximately XX% of the market share

Neonatal tetanus is one of the leading causes of neonatal mortality due to its high fatality rate of 80%-100%. Due to unclean environments and lack of adequate sterile procedures, the disease is more prevalent in rural areas, especially in low-income countries. However, immunization with tetanus toxoid vaccines can prevent neonatal tetanus with the use of DPT vaccines and other pneumococcal conjugate vaccines.

For instance, in April 2023, the U.S. FDA approved PREVNAR 20, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for infants and children. PREVNAR 20 builds on PREVNAR 13 and includes seven additional serotypes associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases, including pertussis, tetanus, and diphtheria.

Geographical Analysis

North America accounted for approximately XX% of the market share in 2022

Tetanus cases are on the rise, and people are becoming more aware of the advantages of vaccination, which is primarily driving the area's market expansion. Other factors influencing the market's expansion include the expanding trend of preventive healthcare and the substantial presence of major vaccine producers in the area. Also, the high rate of healthcare spending and favorable government vaccination program regulations are anticipated to fuel market expansion in North America.

In the United States, a diphtheria-tetanus toxoid (Td) or diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine (Tdap; Adacel or Boostrix) vaccine 0.5 mL intramuscularly (IM) is recommended every 10 years for all adults with complete prior immunization against tetanus and diphtheria. This keeps up with the demand for the vaccine in the United States. Hence, these factors contribute to the growth of the North American toxoid vaccine market throughout the forecast period.

COVID-19 Impact Analysis

The impact of the pandemic on the toxoid vaccine market has been mixed. On one hand, the demand for tetanus toxoid vaccines has remained relatively stable, as these vaccines are included in routine immunization schedules in many countries. On the other hand, the need for diphtheria toxoid vaccines has declined due to the decreased incidence of diphtheria in many parts of the world.

The increase in vaccinations is seen during the COVID-19 pandemic, as there is a high fear of contracting infectious diseases. Many vaccination procedures were halted due to a shift in the focus on the covid 19 pandemic. Overall, the impact of the pandemic on the global toxoid vaccine market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need for vaccination programs to control infectious diseases.

By Disease Type
• Tetanus
• Diphtheria
• Pertussis
• Botulism

By Vaccine Type
• Diphtheria, Tetanus, and Pertussis (DtaP)
• Diphtheria and Tetanus (DT)
• Tetanus, Diphtheria, and Pertussis (Tdap)
• Monovalent Tetanus Toxoid (TT)
• Tetanus and Diphtheria (Td)

By Age Group
• Neonates
• Children
• Adults

By End Users
• Hospitals and Clinics
• Government Organizations
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the toxoid vaccine market include GlaxoSmithKline Plc, Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Sanofi S.A., CSL Seqirus, Dexa Group, Dano Vaccines, Bharat Biotech International Ltd., Abbott Laboratories, and Panacea Biotech among others.

Key Developments
• In September 2022, Serum Institute of India (SII), an Indian multinational pharmaceutical company, submitted its phase 2-3 clinical trial data to the DCGI’s panel for the development of diphtheria, pertussis, and tetanus (Tdap vaccines).
• On October 10, 2022, GSK plc declared that its BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap) has been approved by the US Food and Drug Administration (FDA) for immunization during pregnancy (third trimester) to prevent pertussis in infants aged less than two months.
• In June 2022, the National Health Mission replaced the TT vaccine with the DTaP vaccine in UIP to limit the continuously declining immunity against diphtheria in the population aged 60 years and above.

Why Purchase the Report?
• To visualize the global toxoid vaccine market segmentation based on disease type, vaccine type, age group, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of toxoid vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global toxoid vaccine market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies